
---
title: '《狂犬病疫苗》(专著) 6. 狂犬病疫苗制造(A)'
categories: 
 - 新媒体
 - 科学网
 - 博客
headimg: 'https://picsum.photos/400/300?random=4585'
author: 科学网
comments: false
date: Tue, 30 Mar 2021 11:42:00 GMT
thumbnail: 'https://picsum.photos/400/300?random=4585'
---

<div>   
<h1 style="margin-top:0;margin-right:0;margin-bottom:0;margin-left:0;padding:0 0 0 0 "><strong><span style="font-family: 'Microsoft YaHei';color: #2F496F;letter-spacing: 0;font-size: 29px;background: #FFFFFF"><span style="font-family:Microsoft YaHei">《狂犬病疫苗》</span><span style="font-family:Microsoft YaHei">(专著)</span></span></strong><strong><span style="font-family: 'Microsoft YaHei';color: #2F496F;letter-spacing: 0;font-size: 29px;background: #FFFFFF"> 6</span></strong><strong><span style="font-family: 'Microsoft YaHei';color: #2F496F;letter-spacing: 0;font-size: 29px;background: #FFFFFF"><span style="font-family:Microsoft YaHei">. 狂犬病</span></span></strong><strong><span style="font-family: 'Microsoft YaHei';color: #2F496F;letter-spacing: 0;font-size: 29px;background: #FFFFFF"><span style="font-family:Microsoft YaHei">疫苗制造</span></span></strong><strong><span style="font-family: 'Microsoft YaHei';color: #2F496F;letter-spacing: 0;font-size: 29px;background: #FFFFFF">(</span></strong><strong><span style="font-family: 'Microsoft YaHei';color: #2F496F;letter-spacing: 0;font-size: 29px;background: #FFFFFF"><span style="font-family:Microsoft YaHei">A</span></span></strong><strong><span style="font-family: 'Microsoft YaHei';color: #2F496F;letter-spacing: 0;font-size: 29px;background: #FFFFFF">)</span></strong></h1><h2 style="margin-top:15px;margin-right:0;margin-bottom:23px;margin-left:0;text-indent:47px;padding:0 0 0 0 ;line-height:28px;background:rgb(255,255,255)"><strong><span style="font-family: KaiTi;color: #0070C0;letter-spacing: 0;font-size: 24px"><span style="font-family:KaiTi">大型学术专著《当代新疫苗》（第二版）于去年</span></span></strong><strong><span style="font-family: KaiTi;color: #0070C0;letter-spacing: 0;font-size: 24px"><span style="font-family:KaiTi">3月正式出版。</span></span></strong></h2><h2 style="margin-top:15px;margin-right:0;margin-bottom:23px;margin-left:0;text-indent:47px;padding:0 0 0 0 ;line-height:28px;background:rgb(255,255,255)"><strong><span style="font-family: KaiTi;color: #0070C0;letter-spacing: 0;font-size: 24px"><span style="font-family:KaiTi">本人与中国食品药品检定研究院的李玉华研究员共同撰写了该书第</span><span style="font-family:KaiTi">40章《狂犬病疫苗》。</span></span></strong></h2><h2 style="margin-top:15px;margin-right:0;margin-bottom:23px;margin-left:0;text-indent:42px;padding:0 0 0 0 ;line-height:28px;background:rgb(255,255,255)"><strong><span style="font-family: KaiTi;color: #0070C0;letter-spacing: 0;font-size: 21px"><span style="font-family:KaiTi">本博客将分若干</span></span></strong><strong><span style="font-family: KaiTi;color: #0070C0;letter-spacing: 0;font-size: 21px"><span style="font-family:KaiTi">次全文转载这一章的内容。今天转载的是本章的第</span></span></strong><strong><span style="font-family: KaiTi;color: #0070C0;letter-spacing: 0;font-size: 21px"><span style="font-family:KaiTi">6</span></span></strong><strong><span style="font-family: KaiTi;color: #0070C0;letter-spacing: 0;font-size: 21px"><span style="font-family:KaiTi">节：狂犬病</span></span></strong><strong><span style="font-family: KaiTi;color: #0070C0;letter-spacing: 0;font-size: 21px"><span style="font-family:KaiTi">疫苗制造</span></span></strong><strong><span style="font-family: KaiTi;color: #0070C0;letter-spacing: 0;font-size: 21px">(</span></strong><strong><span style="font-family: KaiTi;color: #0070C0;letter-spacing: 0;font-size: 21px"><span style="font-family:KaiTi">A</span></span></strong><strong><span style="font-family: KaiTi;color: #0070C0;letter-spacing: 0;font-size: 21px">)</span></strong><strong><span style="font-family: KaiTi;color: #0070C0;letter-spacing: 0;font-size: 21px"><span style="font-family:KaiTi">。</span></span></strong></h2><p style="margin-top:15px;margin-right:0;margin-bottom:15px;margin-left:0;text-indent:44px;padding:0 0 0 0 ;text-align:justify;text-justify:inter-ideograph;line-height:28px;background:rgb(255,255,255)"><strong><span style="font-family: 'Microsoft YaHei UI';color: #333333;letter-spacing: 1px;font-size: 29px"><span style="font-family:Microsoft YaHei UI">６</span> <span style="font-family:Microsoft YaHei UI">狂犬病疫苗制造</span> </span></strong></p><p style="margin-top:15px;margin-right:0;margin-bottom:15px;margin-left:0;text-indent:44px;padding:0 0 0 0 ;text-align:justify;text-justify:inter-ideograph;line-height:28px;background:rgb(255,255,255)"><span style="font-family: 'Microsoft YaHei UI';color: #333333;letter-spacing: 1px;font-size: 21px"><span style="font-family:Microsoft YaHei UI">本节目录：</span></span></p><p style="margin-top:15px;margin-right:0;margin-bottom:15px;margin-left:0;text-indent:44px;padding:0 0 0 0 ;text-align:justify;text-justify:inter-ideograph;line-height:28px;background:rgb(255,255,255)"><span style="font-family: 'Microsoft YaHei UI';color: #333333;letter-spacing: 1px;font-size: 21px"><span style="font-family:Microsoft YaHei UI">（</span><span style="font-family:Microsoft YaHei UI">A）</span></span></p><p style="margin-top:15px;margin-right:0;margin-bottom:15px;margin-left:0;text-indent:44px;padding:0 0 0 0 ;text-align:justify;text-justify:inter-ideograph;line-height:28px;background:rgb(255,255,255)"><span style="font-family: 'Microsoft YaHei UI';color: #333333;letter-spacing: 1px;font-size: 21px"><span style="font-family:Microsoft YaHei UI">6.1　狂犬病疫苗发展历程</span></span></p><p style="margin-top:15px;margin-right:0;margin-bottom:15px;margin-left:0;text-indent:44px;padding:0 0 0 0 ;text-align:justify;text-justify:inter-ideograph;line-height:28px;background:rgb(255,255,255)"><span style="font-family: 'Microsoft YaHei UI';color: #333333;letter-spacing: 1px;font-size: 21px"><span style="font-family:Microsoft YaHei UI">6.2  狂犬病疫苗制造概要</span></span></p><p style="margin-top:15px;margin-right:0;margin-bottom:15px;margin-left:0;text-indent:44px;padding:0 0 0 0 ;text-align:justify;text-justify:inter-ideograph;line-height:28px;background:rgb(255,255,255)"><span style="font-family: 'Microsoft YaHei UI';color: #333333;letter-spacing: 1px;font-size: 21px"><span style="font-family:Microsoft YaHei UI">6.3  疫苗生产用细胞</span></span></p><p style="margin-top:15px;margin-right:0;margin-bottom:15px;margin-left:0;text-indent:44px;padding:0 0 0 0 ;text-align:justify;text-justify:inter-ideograph;line-height:28px;background:rgb(255,255,255)"><span style="font-family: 'Microsoft YaHei UI';color: #333333;letter-spacing: 1px;font-size: 21px"><span style="font-family:Microsoft YaHei UI">（</span><span style="font-family:Microsoft YaHei UI">B）</span></span></p><p style="margin-top:15px;margin-right:0;margin-bottom:15px;margin-left:0;text-indent:44px;padding:0 0 0 0 ;text-align:justify;text-justify:inter-ideograph;line-height:28px;background:rgb(255,255,255)"><span style="font-family: 'Microsoft YaHei UI';color: #333333;letter-spacing: 1px;font-size: 21px"><span style="font-family:Microsoft YaHei UI">6.4  疫苗生产用毒株</span></span></p><p style="margin-top:15px;margin-right:0;margin-bottom:15px;margin-left:0;text-indent:44px;padding:0 0 0 0 ;text-align:justify;text-justify:inter-ideograph;line-height:28px;background:rgb(255,255,255)"><span style="font-family: 'Microsoft YaHei UI';color: #333333;letter-spacing: 1px;font-size: 21px"><span style="font-family:Microsoft YaHei UI">6.5  疫苗生产及质量控制</span></span></p><p style="margin-top:15px;margin-right:0;margin-bottom:15px;padding:0 0 0 0 ;text-align:justify;text-justify:inter-ideograph;line-height:28px;background:rgb(255,255,255)"><strong><span style="font-family: 'Microsoft YaHei UI';color: #333333;letter-spacing: 1px;font-size: 21px"><span style="font-family:Microsoft YaHei UI">６</span><span style="font-family:Microsoft YaHei UI">.１ 狂犬病疫苗发展历程</span></span></strong></p><p style="margin-left:0;text-indent:46px;text-autospace:ideograph-numeric;line-height:200%"><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">狂犬病疫苗经历了从神经组织疫苗</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF">(nerve tissue vaccine, NTV)</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">到细胞培养狂犬病疫苗</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF">(cell culture rabies vaccine, CCRV)</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">的历程，至今已有</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF">1</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">35年的历史，相继经历了不灭活的ＮＴＶ（</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF">19</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">世纪</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF">80</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">年代）、灭活的ＮＴＶ（</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF">20</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">世纪初）和ＣＣＲＶ（</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF">20</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">世纪</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF">60</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">年代）等过程</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF">(Wu et al.,2011)</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">。</span></span></strong></p><p style="margin-left:0;text-indent:46px;text-autospace:ideograph-numeric;line-height:200%"><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF">1</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">8</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF">85</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">年，法国微生物学家巴斯德等人研发了世界上第一种可预防人类狂犬病的疫苗。巴斯德将患狂犬病死去的兔子脊髓抽出后自然干燥，发现自然干燥的时间越长，脊髓的毒性就越小。他将放置了</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF">14</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">天的患狂犬病而死的兔子脊髓注射给其他兔子，结果这些兔子随后都能抵御狂犬病病毒的攻击，即便再注射含有病毒的唾液，也不会患狂犬病了</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF">(Wictor,1985)</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">。</span></span></strong></p><p style="margin-left:0;text-indent:46px;text-autospace:ideograph-numeric;line-height:200%"><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">在巴斯德开创性研究后的</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF">70</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">多年中，只有神经组织疫苗（ＮＴＶ）可使用。</span> <span style="font-family:KaiTi">对ＮＴＶ制备方法的改进主要由</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF">Fermi</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">和</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF">Semple</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">完成，他们使用苯酚部分或完全灭活病毒。巴斯德时代，人们就已经认识到含大脑组织的神经组织疫苗的不良反应，以后证实这种反应可能与神经组织中的髓磷质</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF">(myelin)</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">相关。与</span><span style="font-family:KaiTi">“巴斯德法则”相反，除了疫苗中有髓鞘组织而引起的神经并发症外，固定病毒也可能对人类致病；接种神经组织疫苗可引起高达３‰～８‰的变态反应性脑脊髓炎。 之后人们用了75年的时间才证明，免疫后部分患者的瘫痪是由灭活不完全的疫苗株病毒引起的</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF">(Rupprecht & Plotkin, 2018)</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">。</span></span></strong></p><p style="margin-left:0;text-indent:46px;text-autospace:ideograph-numeric;line-height:200%"><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF">1956</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">年，</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF">Fuenzalida</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">及其同事使用新生小鼠大脑制备无髓鞘疫苗，部分拉丁美洲国家在</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF">21</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">世纪初仍在使用这种疫苗。鸭胚疫苗</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF">(duck embryo vaccine, DEV)</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">使用在鸭胚中繁殖的病毒制备，大大减少了免疫后不良反应的发生和严重程度，但是鸭胚疫苗的免疫原性比神经组织疫苗弱。因此，人们迫切需要一种具有高免疫原性的狂犬病疫苗，在小剂量应用时也安全、有效，可以用于基础免疫以及暴露后预防。</span></span></strong></p><p style="margin-left:0;text-indent:46px;text-autospace:ideograph-numeric;line-height:200%"><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF">2004</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">年，ＷＨＯ狂犬病专家磋商会强烈建议停止使用神经组织疫苗，用纯化的细胞培养狂犬病疫苗（ＣＣＲＶ）替代；这些疫苗的暴露前和暴露后的抗体应答率均＞</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF">99</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">％</span> <span style="font-family:KaiTi">，与狂犬病免疫球蛋白（ＲＩＧ）或抗狂犬病血清联合使用，对暴露后高危人群预防狂犬病发生的有效率几乎是</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF">100</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">％</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF">(WHO, 2005)</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">。</span></span></strong></p><p style="margin-left:0;text-indent:46px;text-autospace:ideograph-numeric;line-height:200%"><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF">20</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">世纪</span> </span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF">80</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">年代，我国研制的含有氢氧化铝佐剂的原代地鼠肾细胞疫苗取代羊脑疫苗，由于疫苗未经浓缩和纯化，抗原量少、纯度低，虽然较羊脑疫苗大大降低了副反应，不再出现变态反应性脑脊髓炎，但人体应用后效果不甚理想。</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF">1993</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">年开始使用浓缩</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF">3</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">～</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF">5</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">倍的地鼠肾细胞疫苗，但大面积应用后发现副反应很大，主要原因是疫苗没有经过纯化，杂质含量较高。</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF">1999</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">年，经纯化的地鼠肾细胞疫苗和Ｖｅｒｏ细胞疫苗相继在我国上市（王继麟和严家新，</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF">2001</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">）。</span></span></strong></p><p style="margin-top:15px;margin-right:0;margin-bottom:15px;margin-left:0;text-indent:44px;padding:0 0 0 0 ;text-align:justify;text-justify:inter-ideograph;line-height:28px;background:rgb(255,255,255)"><strong><span style="font-family: 'Microsoft YaHei UI';color: #333333;letter-spacing: 1px;font-size: 21px"><span style="font-family:Microsoft YaHei UI">6.2　 狂犬病疫苗制造概要</span></span></strong></p><p style="margin-left:0;text-indent:46px;text-autospace:ideograph-numeric;line-height:200%"><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">狂犬病疫苗是将狂犬病病毒以适宜的病毒感染量接种细胞后，在适宜的温度下培养一定时间后，收获病毒液；经浓缩、灭活、纯化后，加入一定量的稳定剂制成液体或冻干剂型</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF">(Meslin et al.,1996)</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">，用于预防狂犬病的疫苗。</span></span></strong></p><p style="margin-top:15px;margin-right:0;margin-bottom:15px;margin-left:0;text-indent:44px;padding:0 0 0 0 ;text-align:justify;text-justify:inter-ideograph;line-height:28px;background:rgb(255,255,255)"><strong><span style="font-family: 'Microsoft YaHei UI';color: #333333;letter-spacing: 1px;font-size: 21px"><span style="font-family:Microsoft YaHei UI">6.3　 疫苗生产用细胞</span></span></strong></p><p style="margin-left:0;text-indent:46px;text-autospace:ideograph-numeric;line-height:200%"><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">为了解决神经组织狂犬病疫苗中神经组织引发的安全性问题，</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF">Kissling</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">于</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF">1958</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">年首先尝试使用原代地鼠肾细胞培养狂犬病病毒</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF">(Kissling,1958)</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">。</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF">1950-1960</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">年，开发了鸡胚和鸭胚来源的狂犬病病毒组织疫苗。</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF">1960-1980</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">年，还开发了基于原代牛和狗肾细胞、纯化鸭胚细胞和纯化鸡胚细胞的狂犬病疫苗。</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF">1961</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">年，</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF">Hayfick</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">等人建立了人二倍体细胞株</span> <span style="font-family:KaiTi">ＷＩ３８</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF">(Hayfick et al.,1961)</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">后，</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF">1974</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">年人二倍体细胞（ＷＩ３８、ＭＲＣ５）狂犬病疫苗获得批准，</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF">WHO</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">推荐作为狂犬病疫苗的金标准</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF">(Hayfick,1984)</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">。</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF">1962</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">年，</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF">Yasumura</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">和</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF">Kawikata</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">开发了Ｖｅｒｏ细胞系，</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF">1985</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">年，使用Ｖｅｒｏ细胞生产的狂犬病疫苗ＰＶＲＶ获得批准</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF">(Fournier et al.,1985)</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">。</span></span></strong></p><p style="margin-left:0;text-indent:46px;text-autospace:ideograph-numeric;line-height:200%"><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">当代狂犬病疫苗生产用细胞主要包括以下几种。</span></span></strong></p><p style="margin-top:15px;margin-right:0;margin-bottom:15px;margin-left:0;text-indent:44px;padding:0 0 0 0 ;text-align:justify;text-justify:inter-ideograph;line-height:28px;background:rgb(255,255,255)"><strong><span style="font-family: 'Microsoft YaHei UI';color: #333333;letter-spacing: 1px;font-size: 21px"><span style="font-family:Microsoft YaHei UI">6.3.1原代地鼠肾细胞</span></span></strong></p><p style="margin-left:0;text-indent:46px;text-autospace:ideograph-numeric;line-height:200%"><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">原代地鼠肾细胞疫苗</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF">(primary hamster kidney cell culture vaccine, PHKCV)</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">是第一种被批准的细胞培养狂犬病病疫苗</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF">(CCRV)</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">。狂犬病毒街毒株和固定毒株于</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF">1958</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">年在原代地鼠肾细胞中培养成功。</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF">1968</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">年，加拿大批准使用狂犬病病毒固定毒株ＣＬ６０［来源于美国亚拉巴马州达弗林街（ＳＡＤ）分离株］的ＰＨＫＣＶ（ＳＡＤ株为在ＰＨＫＣ适应后的衍生株）。自</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF">1971</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">年起，苏联使用</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF">Vnukovo 32</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">毒株生产ＰＨＫＣＶ</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF">(Sureau,1987)</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">。</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF">1980</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">年，中国武汉生物制品研究所林放涛教授领导的小组率先研制成功含铝佐剂的ＰＨＫＣＶ</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF">,</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">毒株为北京ａＧ株，使用甲醛灭活。早期产品中最终的成品含有</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF">0.01</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">％</span> <span style="font-family:KaiTi">硫柳汞、</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF">10 mg</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">人血白蛋白和氢氧化铝佐剂。我国于</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF">1980</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">年批准ＰＨＫＣＶ的使用后，完全取代了</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF">Semple</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">型狂犬病神经组织疫苗，使我国狂犬病疫苗的生产赶上了国际先进水平</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF">(Lin et al., 1983)</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">。在随后的</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF">20</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">多年里，我国生产的ＰＨＫＣＶ曾是当时世界上累计生产量最大的狂犬病疫苗，高峰年份每年产销量超过５００万人份。</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF">21</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">世纪以来的产品去除了佐剂，经进一步纯化、浓缩，制备成冻干剂型，并以</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF">5</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">剂免疫方案进行应用。据报道，ＰＨＫＣＶ耐受性良好，可以对证实的狂犬病病毒暴露后患者产生保护作用</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF">(Lin, 1990)</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">。</span></span></strong></p><p style="margin-left:0;text-indent:46px;text-autospace:ideograph-numeric;line-height:200%"><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">地鼠肾细胞的制备：选用</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF">10</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">～</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF">14</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">日龄来自清洁级或清洁级以上地鼠，无菌取肾，剪碎，经胰蛋白酶消化，分散细胞，接种培养瓶，用适宜的培养液进行培养。</span> <span style="font-family:KaiTi">来源于同一批地鼠、同一容器消化制备的地鼠肾细胞为一个细胞消化批。</span> <span style="font-family:KaiTi">源自同一批地鼠、于同一天制备的多个细胞消化批为一个细胞批。</span></span></strong></p><p style="margin-left:0;text-indent:46px;text-autospace:ideograph-numeric;line-height:200%"><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">生产用地鼠应该来自封闭群，</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF">2015</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">版《中国药典》三部要求制备毒种的地鼠应来自ＳＰＦ级，单次病毒收获液制备可以用清洁级地鼠。清洁级地鼠需要排除沙门菌、多杀巴斯德杆菌、支气管鲍特杆菌、泰泽病原体、仙台病毒、淋巴细胞脉络丛脑炎病毒、体外寄生虫、弓形虫全部蠕虫的感染。ＷＨＯ要求用于生产的地鼠应是ＳＰＦ级。ＳＰＦ级地鼠的详细要求见《流行性乙型脑炎减毒活疫苗》标准注释和</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF">2015</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">版《中国药典》通则</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF">3602</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">（国家药典委员会，</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF">2015</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">）。</span></span></strong></p><p style="margin-top:15px;margin-right:0;margin-bottom:15px;margin-left:0;text-indent:44px;padding:0 0 0 0 ;text-align:justify;text-justify:inter-ideograph;line-height:28px;background:rgb(255,255,255)"><strong><span style="font-family: 'Microsoft YaHei UI';color: #333333;letter-spacing: 1px;font-size: 21px"><span style="font-family:Microsoft YaHei UI">6.3.2　 人二倍体细胞</span></span></strong></p><p style="margin-left:0;text-indent:46px;text-autospace:ideograph-numeric;line-height:200%"><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">第一株人二倍体细胞</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF">(human diploid cell, HDC)</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">株ＷＩ３８建立于</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF">1961</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">年。美国费城</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF">Wistar</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">研究所的工作人员用狂犬病病毒ＣＶＳ２４在ＷＩ３８细胞内增殖，以避免使用原代组织培养产生的问题，如对动物蛋白过敏</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF">(Hayflick &Moorheed, 1961)</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">。约２年后，狂犬病病毒ＰＶ株、ＰＭ株、ＨＥＰ株和ＬＥＰ株在ＨＤＣ中能成功持续感染</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF">(Wiktor et al.,1964)</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">。</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF">1974</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">年</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF">12</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">月，法国批准狂犬病病毒人二倍体细胞疫苗（ＨＤＣＶ）上市，随后美国在</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF">1980</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">年</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF">6</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">月也批准了该疫苗</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF">(Bernard et al.,1982)</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">。ＨＤＣＶ是第一种浓缩和冻干的无任何佐剂的狂犬病疫苗，含有人血白蛋白作为稳定剂。ＨＤＣＶ被ＷＨＯ推荐为金标准参考疫苗。与ＤＥＶ、乳鼠大脑或成年动物神经组织疫苗比较，ＨＤＣＶ可以在试验动物和人类中诱发更强烈的免疫应答，较少引起不良反应。迄今为止，仅有极个别的短暂的神经性麻痹疾病案例可能与接种ＨＤＣＶ有某种相关性。</span></span></strong></p><p style="margin-left:0;text-indent:46px;text-autospace:ideograph-numeric;line-height:200%"><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">目前，ＨＤＣＶ使用ＭＲＣ５人胚成纤维细胞进行生产，用</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF">Pitman Moor L503 3M</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">株接种。收获含有病毒的上清液，使用超滤法或超速离心法浓缩</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF">10</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">～</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF">20</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">倍，在病毒灭活前达到大约</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF">10</span></strong><strong><sup><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;vertical-align: super;background: #FFFFFF"><span style="font-family:KaiTi">７</span></span></sup></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">半数致死剂量的滴度，病毒灭活则使用</span><span style="font-family:KaiTi">β丙内酯。 使用ＮＩＨ方法在小鼠中检测疫苗效价，每剂至少为</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF">2.5</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">ＩＵ。</span></span></strong></p><p style="margin-left:0;text-indent:46px;text-autospace:ideograph-numeric;line-height:200%"><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">二倍体细胞株，包括ＷＩ３８、ＭＲＣ５和ＦＲｈＬ２，分裂能力有限（有限寿命是连续传代约</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF">50</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">次），之后细胞衰老，这种现象称为</span><span style="font-family:KaiTi">“</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF">Hayflick</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">极限</span><span style="font-family:KaiTi">”。ＨＤＣＶ成本仍然很高，主要在发达国家使用。</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF">2014</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">年，中国ＨＤＣＶ也获批准上市（蔡勇等，</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF">2015</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">）。</span></span></strong></p><p style="margin-top:15px;margin-right:0;margin-bottom:15px;margin-left:0;text-indent:44px;padding:0 0 0 0 ;text-align:justify;text-justify:inter-ideograph;line-height:28px;background:rgb(255,255,255)"><strong><span style="font-family: 'Microsoft YaHei UI';color: #333333;letter-spacing: 1px;font-size: 21px"><span style="font-family:Microsoft YaHei UI">6.3.3　Ｖｅｒｏ 细胞</span></span></strong></p><p style="margin-left:0;text-indent:46px;text-autospace:ideograph-numeric;line-height:200%"><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">Ｖｅｒｏ细胞（传代细胞）系来源于非洲绿猴肾细胞，于</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF">1962</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">年建立。Ｖｅｒｏ细胞支持狂犬病病毒属多种基因型病毒的感染。</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF">1978</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">年，美国监管当局接受连续传代细胞系用于人用生物制品的生产</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF">(Petricciani et al.,2008)</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">。</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF">20</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">世纪</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF">70</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">年代晚期和</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF">80</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">年代早期，曾以Ｖｅｒｏ细胞为基质生产商业用灭活脊髓灰质炎疫苗。</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF">20</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">世纪</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF">80</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">年代早期，以Ｖｅｒｏ细胞为基质生产狂犬病疫苗</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF">(Roumiantzeff et al.,1984; Suntharasama etal.,1986)</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">。</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF">1985</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">年，欧洲批准法国</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF">Sanofi Pasteur</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">研制的纯化的Ｖｅｒｏ细胞狂犬病疫苗</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF">(pufified Vero cell culture vaccine, PVRV)</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">，并在欧洲和很多发展中国家，如印度和中国获得批准并大量生产。Ｖｅｒｏ细胞的一个优点是可以在微载体上生长和感染，并在发酵罐中培养，可以规模化生产。</span></span></strong></p><p style="margin-left:0;text-indent:46px;text-autospace:ideograph-numeric;line-height:200%"><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">永生细胞系具有几乎无限的生长能力，并且易于大规模培养用于工业生产，但可能被认为具有潜在的致癌性。多年来，Ｖｅｒｏ细胞狂犬病疫苗得到ＷＨＯ和欧盟的肯定，在全球范围内广泛使用，美国在近期也允许该疫苗进入美国市场。</span></span></strong></p><p style="margin-left:0;text-indent:46px;text-autospace:ideograph-numeric;line-height:200%"><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">ＷＨＯ参考Ｖｅｒｏ细胞库是１３４代，推荐用于生产的最大工作细胞代次是１５０代，研究显示，Ｖｅｒｏ细胞传到１６９代仍无致瘤性。</span></span></strong></p><p style="margin-top:15px;margin-right:0;margin-bottom:15px;margin-left:0;text-indent:44px;padding:0 0 0 0 ;text-align:justify;text-justify:inter-ideograph;line-height:28px;background:rgb(255,255,255)"><strong><span style="font-family: 'Microsoft YaHei UI';color: #333333;letter-spacing: 1px;font-size: 21px"><span style="font-family:Microsoft YaHei UI">6.3.4　 纯化鸡胚细胞</span></span></strong></p><p style="margin-left:0;text-indent:46px;text-autospace:ideograph-numeric;line-height:200%"><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">有人将</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF">Novartis(Chiron Behring)</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">公司制造的纯化鸡胚细胞培养疫苗</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF">(purified chicken embryo cell culture vaccine, PCECV)</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">和ＨＤＣＶ对动物和人类的暴露后保护效果进行了评估比较后发现，两种疫苗产生的保护作用没有显著差异。为了制备ＰＣＥＣＶ，研究者将</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF">Flury LEP-C25</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">病毒株在原代鸡胚成纤维细胞中培养。用</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF">0.025</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">％</span><span style="font-family:KaiTi">β丙内酯灭活，然后使用密度梯度离心法浓缩并纯化。真空冻干疫苗含有处理过的明胶作为稳定剂。ＰＣＥＣＶ已在全世界注册（包括美国），并且已经使用了</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF">8000</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">万剂。复溶研究显示，用水复溶后的疫苗在冰箱中至少１周内可以保持稳定（王月等，</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF">2012</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">）。</span></span></strong></p><p style="margin-left:0;text-indent:46px;text-autospace:ideograph-numeric;line-height:200%"><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">在美国、德国、英国、泰国、克罗地亚和印度，人们对ＰＣＥＣＶ进行了广泛的试验。</span> <span style="font-family:KaiTi">第一种纯化鸡胚细胞培养疫苗</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF">Rabipur</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">于</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF">1984</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">年在德国获准注册，在过去的</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF">30</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">多年超过</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF">60</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">个国家使用的临床经验表明，该疫苗具有良好的免疫原性，既有效又安全。印度使用ＰＣＥＣＶ已经超过</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF">10</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">年，疫苗的耐受性良好；其中，在</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF">1375</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">名使用者中只有</span> </span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF">4</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">％</span> <span style="font-family:KaiTi">报告有副反应，尽管也曾观察到一些荨麻疹病例。疫苗的免疫原性良好，暴露后预防的中和抗体几何平均滴度（ＧＭＴ）约为</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF">4 IU</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">，只有</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF">0.9</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">％的患者其抗体滴度低于</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF">1IU(Giesen et al.,2015; Recuenco et al.,2017)</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #333333;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:KaiTi">。</span></span></strong></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:47px;padding:0 0 0 0 ;line-height:28px;background:rgb(255,255,255)"><strong><span style="font-family: SimSun;color: #333333;letter-spacing: 0;font-size: 24px"><span style="font-family:SimSun">相关博文：</span></span></strong></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:48px;padding:0 0 0 0 ;line-height:28px;background:rgb(255,255,255)"><a href="http://blog.sciencenet.cn/home.php?mod=space&uid=347754&do=blog&id=1277395" target="_blank"><span style="font-family: Tahoma;color: #6666CC;letter-spacing: 0;font-size: 20px"><span style="font-family:Tahoma">《狂犬病疫苗》专著共享</span></span></a><span style="font-family: SimSun;color: #6666CC;letter-spacing: 0;font-size: 14px"> </span><span style="font-family: Tahoma;color: #666666;letter-spacing: 0;font-size: 20px"> 2021-03-18</span></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:49px;padding:0 0 0 0 ;line-height:28px;background:rgb(255,255,255)"><a href="http://blog.sciencenet.cn/home.php?mod=space&uid=347754&do=blog&id=1277585" target="_blank"><span style="font-family: Tahoma;color: #6666CC;letter-spacing: 0;font-size: 20px"><span style="font-family:Tahoma">《狂犬病疫苗》</span>(专著共享) 1. 概述</span></a><span style="font-family: Tahoma;color: #666666;letter-spacing: 0;font-size: 20px"> </span><span style="font-family: SimSun;color: #666666;letter-spacing: 0;font-size: 20px"> </span><span style="font-family: Tahoma;color: #666666;letter-spacing: 0;font-size: 20px">2021-03-19</span></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:49px;padding:0 0 0 0 ;line-height:28px;background:rgb(255,255,255)"><a href="http://blog.sciencenet.cn/home.php?mod=space&uid=347754&do=blog&id=1277814" target="_blank"><span style="text-decoration:underline;"><span style="font-family: Tahoma;color: #6666CC;letter-spacing: 0;font-size: 20px"><span style="font-family:Tahoma">《狂犬病疫苗》</span>(专著共享) 2.病原学</span></span></a><span style="font-family: Tahoma;color: #666666;letter-spacing: 0;font-size: 20px"> </span><span style="font-family: SimSun;color: #666666;letter-spacing: 0;font-size: 20px"> </span><span style="font-family: Tahoma;color: #666666;letter-spacing: 0;font-size: 20px">2021-03-21</span></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:50px;padding:0 0 0 0 ;background:rgb(255,255,255)"><a href="http://blog.sciencenet.cn/home.php?mod=space&uid=347754&do=blog&id=1277951" target="_blank"><span style="text-decoration:underline;"><span style="font-family: Tahoma;color: #6666CC;letter-spacing: 0;font-size: 20px"><span style="font-family:Tahoma">《狂犬病疫苗》</span>(专著共享) 3.流行病学</span></span></a><span style="font-family: Tahoma;color: #666666;letter-spacing: 0;font-size: 20px"> 2021-03-22</span><a href="http://blog.sciencenet.cn/home.php?mod=space&uid=347754&do=blog&id=1278323" target="_blank"></a></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:50px;padding:0 0 0 0 ;background:rgb(255,255,255)"><strong><span style="font-family: Tahoma;color: #6666CC;letter-spacing: 0;font-size: 20px"><span style="font-family:Tahoma">《狂犬病疫苗》</span>(专著) 4. 发病机理与疫苗免疫应答</span></strong><span style="font-family: Tahoma;color: #666666;letter-spacing: 0;font-size: 20px"> 2021-03-24</span></p><p style="margin-left: 0px; text-indent: 46px; line-height: 200%;"><a href="http://blog.sciencenet.cn/home.php?mod=space&uid=347754&do=blog&id=1278633" target="_blank"><strong><span style="text-decoration:underline;"><span style="font-family: Tahoma;line-height: 200%;color: #6666CC;letter-spacing: 0;font-size: 20px;background: #FFFFFF"><span style="font-family:Tahoma">《狂犬病疫苗》</span>(专著) 5. 狂犬病的症状和临床诊断</span></span></strong></a><span style="font-family: Tahoma;line-height: 200%;color: #666666;letter-spacing: 0;font-size: 20px;background: #FFFFFF"> 2021-03-26</span></p>                    <br><br>
                                        <label style="font-size:13px; color:#850f0f">转载本文请联系原作者获取授权，同时请注明本文来自严家新科学网博客。<br>链接地址：</label><a href="http://blog.sciencenet.cn/blog-347754-1279308.html" target="_blank" style="font-size:13px; color:#850f0f">http://blog.sciencenet.cn/blog-347754-1279308.html </a>
  <br><br>上一篇：<a href="http://blog.sciencenet.cn/blog-347754-1278784.html" target="_black">第二代新冠病毒疫苗的发展方向： 充分发挥T细胞的作用！</a><br>                    <!--大赛结束-->
                                        
  
</div>
            